Jefferies valuates Bavarian Nordic's Covid-19 project
Following Bavarian Nordic's capital raising round for developing the company's Covid-19 vaccine, and its fiscal report presentation, financial analyst Jefferies is ready to start incorporating the value of the vaccine into its company valuation.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Financial services company Jefferies now adds value to Bavarian Nordic's Covid-19 vaccine ABNCoV2 and valuates the developmental project, which was in-licensed from Adaptvac, at DKK 25 (USD 4.0) per share, according to a Friday note relating to Bavarian's financial report. According to Jefferies, this was pretty much what the analyst firm expected, especially since Bavarian had already presented its preliminary figures in January.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic's 2021 will be full of development
For subscribers
